Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colorectal cancer screening

This article was originally published in The Gray Sheet

Executive Summary

A blood test using Loss of Imprinting (LoI) of the insulin-like growth factor II gene may be used as a marker of colorectal cancer risk, Johns Hopkins researchers report in Science March 14. In the pilot study of 172 patients who had previously undergone colonoscopies, subjects with a family history of colon cancer were five times more likely to have the LoI marker, while those with polyps were three times more likely. LoI was found in 30% of colorectal cancer patients but only 10% of healthy individuals...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT018032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel